Pharmaceutical firm Venus Remedies Ltd, today said it has received Indian product patent for its antibiotic research product Vancoplus. The Indian Patent Office (IPO) granted the licence which is valid till 2025, said Venus.
Pharmaceutical firm Venus Remedies Ltd, today said it has received Indian product patent for its antibiotic research product Vancoplus. The Indian Patent Office (IPO) granted the licence which is valid till 2025, said Venus. Vancoplus is a novel antibiotic entity that is highly effective against the notorious MRSA (methicillin-resistant staphylococcus aureus) bacterial strain and multi-drug resistant microbes primarily responsible for causing infections like meningitis, pneumonia, typhoid, septicemia, urinary tract ailments and skin diseases, the company said.
"The research took more than seven years to develop this product. It is one of the best and safest options to get rid of drug-resistant gram-negative and gram-positive bacteria, MRSA, vancomycin-intermediate staphylococcus aureus (VISA) and heterogeneous glycopeptide-intermediate staphylococcus aureus (hGISA)," Venus Remedies Joint Managing Director Manu Chaudhary said in a statement here. The total global market size of MRSA-associated infections is around USD 9 billion.
At present, it is growing at 4.8 per cent, which is estimated to go up to 12.4 percent by 2017. In India, Vancoplus is projected to cater to a market of Rs 214 crore by 2018-19. So far, Venus has received patents for Vancoplus from more than 18 countries, including USA, Japan, South Africa, New Zealand, Ukraine and Australia.
It is holding discussions with some multinational companies for the outlicencing of this product, the release added.
Venus Remedies stock price
On February 09, 2015, Venus Remedies closed at Rs 184.45, up Rs 21.55, or 13.23 percent. The 52-week high of the share was Rs 381.75 and the 52-week low was Rs 151.50.
The company's trailing 12-month (TTM) EPS was at Rs 45.35 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 4.07. The latest book value of the company is Rs 408.51 per share. At current value, the price-to-book value of the company is 0.45.
Anda sedang membaca artikel tentang
Venus Remedies bags Indian patent for antibiotic Vancoplus
Dengan url
http://gayafashionshow.blogspot.com/2015/02/venus-remedies-bags-indian-patent-for.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Venus Remedies bags Indian patent for antibiotic Vancoplus
namun jangan lupa untuk meletakkan link
Venus Remedies bags Indian patent for antibiotic Vancoplus
sebagai sumbernya
0 komentar:
Posting Komentar